CN101820878B - 用于治疗创伤后应激障碍的四氢喹啉衍生物 - Google Patents

用于治疗创伤后应激障碍的四氢喹啉衍生物 Download PDF

Info

Publication number
CN101820878B
CN101820878B CN2008801113334A CN200880111333A CN101820878B CN 101820878 B CN101820878 B CN 101820878B CN 2008801113334 A CN2008801113334 A CN 2008801113334A CN 200880111333 A CN200880111333 A CN 200880111333A CN 101820878 B CN101820878 B CN 101820878B
Authority
CN
China
Prior art keywords
formula
pharmaceutically acceptable
compound
phenyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801113334A
Other languages
English (en)
Chinese (zh)
Other versions
CN101820878A (zh
Inventor
弗兰克西斯·杰克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101820878(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN101820878A publication Critical patent/CN101820878A/zh
Application granted granted Critical
Publication of CN101820878B publication Critical patent/CN101820878B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2008801113334A 2007-10-10 2008-10-09 用于治疗创伤后应激障碍的四氢喹啉衍生物 Expired - Fee Related CN101820878B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007054130 2007-10-10
WOPCT/IB2007/054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (2)

Publication Number Publication Date
CN101820878A CN101820878A (zh) 2010-09-01
CN101820878B true CN101820878B (zh) 2012-02-01

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801113334A Expired - Fee Related CN101820878B (zh) 2007-10-10 2008-10-09 用于治疗创伤后应激障碍的四氢喹啉衍生物

Country Status (27)

Country Link
US (1) US9532985B2 (https=)
EP (1) EP2207550B1 (https=)
JP (1) JP5883222B2 (https=)
KR (1) KR101733247B1 (https=)
CN (1) CN101820878B (https=)
AR (1) AR068768A1 (https=)
AU (1) AU2008309194B2 (https=)
BR (1) BRPI0818617A2 (https=)
CA (1) CA2699504C (https=)
CY (1) CY1114799T1 (https=)
DK (1) DK2207550T3 (https=)
EA (1) EA017443B1 (https=)
ES (1) ES2444418T3 (https=)
HR (1) HRP20140214T1 (https=)
IL (1) IL204838A (https=)
MA (1) MA31800B1 (https=)
MX (1) MX2010003711A (https=)
MY (1) MY153044A (https=)
NZ (1) NZ585086A (https=)
PE (1) PE20091010A1 (https=)
PL (1) PL2207550T3 (https=)
PT (1) PT2207550E (https=)
SI (1) SI2207550T1 (https=)
TW (1) TWI428129B (https=)
UA (1) UA99150C2 (https=)
WO (1) WO2009047723A2 (https=)
ZA (1) ZA201003251B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078291A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
CN102076694A (zh) 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
CA2815179A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
CA2823877C (en) 2011-02-18 2020-01-07 Idorsia Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
ES2572703T3 (es) 2011-11-08 2016-06-01 Actelion Pharmaceuticals Ltd. Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
EA201500399A1 (ru) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MY179862A (en) 2013-12-03 2020-11-18 Idorsia Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
AR129309A1 (es) 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1416420A (zh) * 2000-03-14 2003-05-07 埃科特莱茵药品有限公司 1,2,3,4－四氢异喹啉的衍生物
CN1764647A (zh) * 2003-03-26 2006-04-26 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
CN1926109A (zh) * 2004-03-01 2007-03-07 埃科特莱茵药品有限公司 经取代的1,2,3,4－四氢异喹啉衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1416420A (zh) * 2000-03-14 2003-05-07 埃科特莱茵药品有限公司 1,2,3,4－四氢异喹啉的衍生物
CN1764647A (zh) * 2003-03-26 2006-04-26 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
CN1926109A (zh) * 2004-03-01 2007-03-07 埃科特莱茵药品有限公司 经取代的1,2,3,4－四氢异喹啉衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
翟金国等.创伤后应激障碍药物治疗进展.《中国医院药学杂志》.2005,第25卷(第10期),962-964. *

Also Published As

Publication number Publication date
CY1114799T1 (el) 2016-12-14
ES2444418T3 (es) 2014-02-25
CA2699504C (en) 2015-11-24
PE20091010A1 (es) 2009-08-08
JP2011500550A (ja) 2011-01-06
PT2207550E (pt) 2014-02-07
MX2010003711A (es) 2010-04-30
BRPI0818617A2 (pt) 2015-04-07
US9532985B2 (en) 2017-01-03
AU2008309194A1 (en) 2009-04-16
EP2207550A2 (en) 2010-07-21
AU2008309194B2 (en) 2013-10-03
MY153044A (en) 2014-12-31
EA017443B1 (ru) 2012-12-28
TWI428129B (zh) 2014-03-01
DK2207550T3 (da) 2014-01-27
WO2009047723A2 (en) 2009-04-16
AR068768A1 (es) 2009-12-02
IL204838A0 (en) 2010-11-30
MA31800B1 (fr) 2010-10-01
SI2207550T1 (sl) 2014-03-31
HK1145440A1 (en) 2011-04-21
IL204838A (en) 2014-09-30
EA201000557A1 (ru) 2010-10-29
EP2207550B1 (en) 2013-12-11
TW200932231A (en) 2009-08-01
ZA201003251B (en) 2011-07-27
KR101733247B1 (ko) 2017-05-08
US20100234420A1 (en) 2010-09-16
WO2009047723A3 (en) 2009-05-28
CA2699504A1 (en) 2009-04-16
HRP20140214T1 (hr) 2014-04-11
UA99150C2 (ru) 2012-07-25
NZ585086A (en) 2012-03-30
JP5883222B2 (ja) 2016-03-09
KR20100065203A (ko) 2010-06-15
PL2207550T3 (pl) 2014-05-30
CN101820878A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
CN101820878B (zh) 用于治疗创伤后应激障碍的四氢喹啉衍生物
JP2003510273A (ja) 神経障害性の疼痛の治療のためのレチガビンの使用
JP2009525979A (ja) ４−アシルアミノピリジン誘導体を介した神経新生
SK287180B6 (sk) Kombinácia účinných látok na medikamentóznu terapiu návykových alebo omamných prostriedkov
Furukawa et al. The glutamate AMPA receptor antagonist, YM872, attenuates cortical tissue loss, regional cerebral edema, and neurological motor deficits after experimental brain injury in rats
EP3458039B1 (en) Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
KR102023748B1 (ko) 순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물
CN1230178C (zh) 伴有前列腺肥大症的膀胱刺激症状治疗药
CN100354274C (zh) 神经变性疾病的预防和治疗药物
KR102040639B1 (ko) 히스타민-3 수용체 역효능제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
Sévoz-Couche et al. Antinociceptive effect of cardiopulmonary chemoreceptor and baroreceptor reflex activation in the rat
JP2002524509A (ja) 新規組成物
HK1145440B (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
TWI334349B (en) Pain threshold reduction depressant
CN107648235B (zh) 普纳替尼在制备治疗缺血/再灌注损伤药物中的应用
WO2025102989A1 (zh) 靶向O-GlcNAc糖苷水解酶抑制剂促进髓鞘再生
AU2016400019A1 (en) Negative allosteric modulators of mGluR5 for use in the treatment of mature brain damages.
CA3018375C (en) Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
JP2023539391A (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
IL293373A (en) Behavioral and psychological symptom treatment methods in dementia patients
WO2006115302A1 (ja) 神経因性疼痛治療剤
CZ2001961A3 (cs) Nový prostředek
TW201924677A (zh) 苯并咪唑衍生物用於夜間酸突破的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200518

Address after: Swiss A Schriewer

Patentee after: ACTELION PHARMACEUTICALS Ltd.

Address before: Swiss A Skei Weil

Patentee before: ACTELION PHARMACEUTICALS Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120201